
The White House announced an Executive Order to accelerate research and broaden access to certain psychedelic drugs as promising treatments for serious mental illnesses, emphasizing help for veterans. Emerging clinical data showing rapid reductions in suicidal ideation after a ketamine infusion plus low-dose buprenorphine reinforce the administration’s framing of ‘‘breakthrough’’ drug therapies and may shape research priorities, funding decisions, and considerations of access for high-risk populations including veterans.
Click a connection line between nodes to view confidence and evidence.